DR. REDDY’S LABORATORIES LTD.

Submitted to :- Sourav Kinra Subject :- Financial Management Type :- Pitch Book

Submitted by :- swati sharma Roll no. :- 20421074 Class :- MBA - 1
DR. REDDY’S LABORATORIES – HYDERABAD, TELANGANA

Company Overview Stock Performance

Trading stats
● Dr. Reddy's Laboratories is an Indian
Current price ₹86.55 05/07/2021
multinational pharmaceutical company. The 52 week high ₹106.55 19/05/2021
company was founded by Anji Reddy, who 52 week low ₹22.58 06/07/2020

previously worked in the mentor institute Indian

and Drugs and Pharmaceuticals limited.
● Over 190 medications, 60 active pharmaceutical
ingredients(api) for drug manufacture, diagnostic
kits and critical care units
● To bring new molecules into the country at a price
the common man can afford 
● Global workforce-20000+
● Commercial presence-26 countries
● DRL and Cheminor together generated $12.5
million in sales by 1990
 Key Management Enterprise Value Analysis(₹ in crores)

● Chairman & Managing Director : G V Market cap (intra- 905.15B

Prasad day) 5
● Chairman : Mr. K Satish Reddy Price/sales (ttm) 4.77
● CEO : Mr.Erez Israeli Price/book (mrq) 5.17
● CFO : Mr. Parag Agarwal Enterprise
4.62
● Independent Director : MS. Kalpana value/revenue 3
Morparia Enterprise
19.14
● Independent Director : Mr. Sridar value/EBITDA 7
Lyengar
● Independent Director : Mr. Allan
Oberman
● Company Secretary : Mr. Sandeep
Poddar
Financial overview
Financial year FY 2017 FY 2018 FY 2019 FY 2020 FY 2021

Total revenue 14,36.60 14,436.20 15,829.50 18,193.70 19,386.90

EBITDA 2,643.70 2,506.40 3,559.50 3,147.10 4209.30

PBIT 1,617.10 1,429.20 2,424.70 1,984.00 2,980.50

PBT 1,553.70 1,350.40 2,335.80 1,885.70 2,883.50

Net income 1,292.10 946.80 1,950.00 2,026.00 1,951.60

EPS 76.83 57.10 117.48 121.96 117.40

DPS 20.00 0.35 20.00 25.00 25.00

 Milestones
• 1984. The birth of a dream. Scientist and entrepreneur Dr.
• 1991. Moving up the value chain.
• 1995. Charting new territories.
• 2001. Spreading our wings.
• 2007. Accelerating access to expensive therapies.
• 2010. Setting new benchmarks.
• 2014. Keeping our promises.
• 2020. Making a mark.
 Products
Products associated with Dr Reddy's Laboratories Ltd

Ordway International is the leading pharmaceutical wholesaler & supplier of branded & generic medicines in
form of Tablets, Syrups, Oral Suspension, Injectable, eye drops, nasal spray, Intravenous Infusion,
Ointments & others at competitive prices all over the world including counties USA, UK, China, Hong
Kong, Australia, Thailand, Malaysia, Singapore, Philippines, Vietnam, Indonesia, Cambodia, Russia, UAE,
Saudi Arabia, Nigeria, Kenya, Romania, Bulgaria, Chile, Ecuador, Middle East, Congo, Iraq, Iran,
Afghanistan etc.
We supply products manufactured by Dr. Reddy's Laboratories at wholesale prices to Pharmaceutical
Distributors, online / brick & mortar Pharmacy, Private Hospitals and Clinics, Government Health
Departments, Non-Governmental Organisations, R&D Labs in both Bulk & small quantities for reselling,
trading, wholesale supply, Tenders Supply, Clinical Trials, Comparator trials, Bio similar, Named
Patient Supplies.
 Strengths :

S • Company launched Peg-grafeelTM, an inexpensive variety of peg filgrastim, used to

fight infection in chemotherapy where company has sold some 1.5 million units of it. 
• Dowpharma/Chirotech acquisition provided proprietary chiral and biocatalysts
technology 
• The acquisition of Beta pharma helped to introduce an array of generic products and
show its presence in the European markets.

Weaknesses :

W
• Discovery of drugs is a highly unpredictable business
• Strict govt regulations and policies affects operational efficiency

Opportunities :

O •

•
 Leverage Biologics & Cytotoxic Infrastructure to deal with the need of Oncology
Market 
New partnerships to develop Biosimilar business 

T
Threats :

• Preliminary investment for Drug discovery is very high

• long gestational period for new drug development
• increasingly stringent regulations for new drug development
DR. REDDY’S LABORTORIES.LTD

Acquisition Timeline
announced that
Acquired Pharma Acquired a the Acquired
it had settled company filed 19
ceutical Acquired Levo company
its claims new Abbreviated
Ingredients cetirizine launched 21
against New Drug
tablets in US Applications new brands
Nordion Inc.
in India.

1986 2007 OCT 2010 2011 May,2012 march,2015 march,2017 Oct,2018 Oct,2019 Dec,2019

quired 100% stake in

Shipped its Acquired Imperial Credit Private
Acquired Limited a Non-Banking Acquired a
first Israel–based Quetiapine
consignment Fumarate Finance Company amount of Rs
clinical–stage (NBFC) based out ofAc 15607 million or
of methyldopa developer  Tablets. 
Kolkata for a 10.1% of revenue
drug to west consideration of Rs 2.05
Germany versus 12.9%
crore